Gen-Probe/NNP Inc./NNP ,/, a/DT biotechnology/NN concern/NN ,/, said/VBD 0/-NONE- it/PRP signed/VBD a/DT definitive/JJ agreement/NN */-NONE- to/TO be/VB acquired/VBN *-1/-NONE- by/IN Chugai/NNP Pharmaceutical/NNP Co./NNP of/IN Tokyo/NNP for/IN about/RB $/$ 110/CD million/CD *U*/-NONE- ,/, or/CC almost/RB double/RB the/DT market/NN price/NN of/IN Gen-Probe/NNP 's/POS stock/NN ./.
The/DT move/NN is/VBZ sure/JJ *-1/-NONE- to/TO heighten/VB concerns/NNS about/IN increased/VBN Japanese/JJ investment/NN in/IN U.S./NNP biotechnology/NN firms/NNS ./.
It/PRP is/VBZ also/RB likely/JJ *-1/-NONE- to/TO bolster/VB fears/NNS that/IN the/DT Japanese/NNP will/MD use/VB their/PRP$ foothold/NN in/IN U.S./NNP biotechnology/NN concerns/NNS *-2/-NONE- to/TO gain/VB certain/JJ trade/NN and/CC competitive/JJ advantages/NNS ./.
Gen-Probe/NNP ,/, an/DT industry/NN leader/NN in/IN the/DT field/NN of/IN genetic/JJ probes/NNS ,/, which/WDT *T*-2/-NONE- is/VBZ a/DT new/JJ technology/NN used/VBN */-NONE- in/IN diagnostic/JJ tests/NNS ,/, last/JJ year/NN signed/VBD an/DT agreement/NN for/IN Chugai/NNP to/TO exclusively/RB market/VB its/PRP$ diagnostic/JJ products/NNS *ICH*-1/-NONE- in/IN Japan/NNP for/IN infectious/JJ diseases/NNS and/CC cancer/NN ./.
Chugai/NNP agreed/VBD then/RB *-1/-NONE- to/TO fund/VB certain/JJ associated/VBN research/NN and/CC development/NN costs/NNS ./.
That/DT arrangement/NN apparently/RB has/VBZ worked/VBN well/RB ,/, and/CC Thomas/NNP A./NNP Bologna/NNP ,/, president/NN and/CC chief/JJ executive/JJ officer/NN of/IN Gen-Probe/NNP ,/, founded/VBN */-NONE- in/IN 1983/CD ,/, said/VBD 0/-NONE- the/DT sale/NN of/IN the/DT company/NN means/VBZ 0/-NONE- ``/`` we/PRP will/MD be/VB able/JJ *-1/-NONE- to/TO concentrate/VB on/IN */-NONE- running/VBG the/DT business/NN rather/RB than/IN always/RB looking/VBG for/IN sources/NNS of/IN financing/NN ./. ''/''
Chugai/NNP agreed/VBD *-1/-NONE- to/TO pay/VB $/$ 6.25/CD *U*/-NONE- a/DT share/NN for/IN Gen-Probe/NNP 's/POS 17.6/CD million/CD common/JJ shares/NNS outstanding/JJ on/IN a/DT fully/RB diluted/VBN basis/NN ./.
Yesterday/NN ,/, in/IN national/JJ trading/NN in/IN the/DT over-the-counter/JJ market/NN ,/, Gen-Probe/NNP common/NN closed/VBD at/IN $/$ 3.25/CD *U*/-NONE- a/DT share/NN ./.
Because/IN the/DT U.S./NNP leads/VBZ in/IN most/JJS areas/NNS of/IN biotechnology/NN --/: largely/RB because/IN of/IN research/NN investment/NN by/IN the/DT U.S./NNP government/NN --/: the/DT sale/NN is/VBZ sure/JJ *-1/-NONE- to/TO increase/VB concerns/NNS that/IN Japanese/JJ companies/NNS will/MD buy/VB American/NNP know-how/NN and/CC use/VB it/PRP *-2/-NONE- to/TO obtain/VB the/DT upper/JJ hand/NN in/IN biotechnology/NN trade/NN and/CC competition/NN ./.
``/`` The/DT biotechnology/NN firms/NNS may/MD be/VB setting/VBG up/RP their/PRP$ own/JJ competitors/NNS ,/, ''/'' said/VBD *T*-1/-NONE- Richard/NNP Godown/NNP ,/, president/NN of/IN the/DT Industrial/NNP Biotechnology/NNP Association/NNP ./.
He/PRP added/VBD that/IN until/IN now/RB the/DT Japanese/NNS have/VBP only/RB acquired/VBN equity/NN positions/NNS in/IN U.S./NNP biotechnology/NN companies/NNS ./.
``/`` They/PRP are/VBP piggybacking/VBG onto/IN developed/VBN technology/NN ,/, ''/'' he/PRP said/VBD *T*-1/-NONE- ./.
During/IN the/DT past/JJ five/CD years/NNS ,/, Japanese/JJ concerns/NNS have/VBP invested/VBN in/IN several/JJ of/IN the/DT U.S./NNP 's/POS 431/CD independent/JJ biotechnology/NN companies/NNS ./.
Chugai/NNP has/VBZ been/VBN one/CD of/IN the/DT most/RBS active/JJ Japanese/JJ players/NNS in/IN U.S./NNP biotechnology/NN companies/NNS ;/: it/PRP has/VBZ an/DT equity/NN investment/NN in/IN Genetics/NNP Institute/NNP Inc./NNP ,/, Cambridge/NNP ,/, Mass./NNP ,/, and/CC a/DT joint-venture/JJ agreement/NN with/IN Upjohn/NNP Co./NNP ,/, Kalamazoo/NNP ,/, Mich/NNP ./.
The/DT Japanese/JJ government/NN ,/, Mr./NNP Godown/NNP said/VBD 0/-NONE- *T*-1/-NONE- ,/, has/VBZ stated/VBN that/IN it/PRP wants/VBZ 10/CD %/NN to/TO 11/CD %/NN *U*/-NONE- of/IN its/PRP$ gross/JJ national/JJ product/NN to/TO come/VB from/IN biotechnology/NN products/NNS ./.
``/`` It/PRP is/VBZ becoming/VBG more/JJR of/IN a/DT horse/NN race/NN *ICH*-2/-NONE- every/DT day/NN between/IN the/DT U.S./NNP and/CC Japan/NNP ,/, ''/'' he/PRP said/VBD *T*-1/-NONE- ,/, *-3/-NONE- adding/VBG that/IN some/DT fear/VBP that/IN as/IN with/IN the/DT semiconductor/NN ,/, electronics/NNS ,/, and/CC automobile/NN industries/NNS ,/, Japanese/JJ companies/NNS will/MD use/VB U.S.-developed/JJ technology/NN *-4/-NONE- to/TO gain/VB trade/NN advantages/NNS ./.
Mr./NNP Bologna/NNP said/VBD 0/-NONE- the/DT sale/NN would/MD allow/VB Gen-Probe/NNP to/TO speed/VB up/RP the/DT development/NN of/IN new/JJ technology/NN ,/, and/CC to/TO more/RBR quickly/RB apply/VB existing/VBG technology/NN to/TO an/DT array/NN of/IN diagnostic/JJ products/NNS 0/-NONE- the/DT company/NN wants/VBZ *-3/-NONE- to/TO offer/VB *T*-2/-NONE- ./.
By/IN 1988/CD ,/, when/WRB only/RB 10/CD genetic/JJ probe-based/JJ tests/NNS of/IN diagnostic/JJ infectious/JJ diseases/NNS of/IN humans/NNS had/VBD been/VBN approved/VBN *-2/-NONE- for/IN marketing/VBG by/IN the/DT Food/NNP and/CC Drug/NNP Administration/NNP *T*-3/-NONE- ,/, eight/CD of/IN them/PRP had/VBD been/VBN developed/VBN and/CC sold/VBN *-4/-NONE- by/IN Gen-Probe/NNP ./.
Osamu/NNP Nagayama/NNP ,/, deputy/NN president/NN of/IN Chugai/NNP ,/, which/WDT *T*-1/-NONE- spends/VBZ about/RB 15/CD %/NN of/IN its/PRP$ sales/NNS on/IN research/NN and/CC development/NN ,/, was/VBD unable/JJ *-3/-NONE- to/TO pinpoint/VB how/WRB much/JJ money/NN Chugai/NNP would/MD pump/VB *T*-2/-NONE- into/IN Gen-Probe/NNP ./.
``/`` We/PRP think/VBP 0/-NONE- Gen-Probe/NNP has/VBZ technology/NN important/JJ to/TO people/NNS 's/POS health/NN ,/, ''/'' he/PRP said/VBD *T*-1/-NONE- ,/, *-3/-NONE- adding/VBG :/: ``/`` We/PRP think/VBP 0/-NONE- it/PRP *EXP*-4/-NONE- is/VBZ important/JJ for/IN us/PRP to/TO have/VB such/JJ technology/NN ./. ''/''
He/PRP and/CC Mr./NNP Bologna/NNP emphasized/VBD that/IN both/DT companies/NNS would/MD gain/VB technological/JJ knowledge/NN through/IN the/DT sale/NN of/IN Gen-Probe/NNP ,/, which/WDT *T*-1/-NONE- will/MD expand/VB ``/`` significantly/RB ''/'' as/IN a/DT result/NN of/IN the/DT acquisition/NN ./.
In/IN 1988/CD ,/, Chugai/NNP had/VBD net/JJ income/NN of/IN $/$ 60/CD million/CD *U*/-NONE- on/IN revenue/NN of/IN $/$ 991/CD million/CD *U*/-NONE- ./.
GenProbe/NN had/VBD a/DT net/JJ loss/NN of/IN $/$ 9.5/CD million/CD *U*/-NONE- on/IN revenue/NN of/IN $/$ 5.8/CD million/CD *U*/-NONE- ./.
Recently/RB ,/, Gen-Probe/NNP received/VBD a/DT broad/JJ U.S./NNP patent/NN for/IN a/DT technology/NN that/WDT *T*-2/-NONE- helps/VBZ detect/VB ,/, identify/VB and/CC quantify/VB non-viral/JJ organisms/NNS through/IN the/DT targeting/VBG of/IN a/DT form/NN of/IN genetic/JJ material/NN called/VBN */-NONE- ribosomal/JJ RNA/NNP ./.
Among/IN other/JJ things/NNS ,/, Mr./NNP Bologna/NNP said/VBD that/IN the/DT sale/NN will/MD facilitate/VB Gen-Probe/NNP 's/POS marketing/NN of/IN a/DT diagnostic/JJ test/NN for/IN acquired/VBN immune/JJ deficiency/NN syndrome/NN ,/, or/CC AIDS/NNP ./.
Chugai/NNP also/RB will/MD help/VB Gen-Probe/NNP with/IN its/PRP$ regulatory/JJ and/CC marketing/NN expertise/NN in/IN Asia/NNP ,/, Mr./NNP Bologna/NNP said/VBD 0/-NONE- *T*-1/-NONE- ./.
The/DT tender/NN offer/NN for/IN Gen-Probe/NNP 's/POS shares/NNS is/VBZ expected/VBN *-1/-NONE- to/TO begin/VB next/JJ Monday/NNP ,/, the/DT company/NN said/VBD 0/-NONE- *T*-2/-NONE- ./.

